Skip to main content

Table 2 Core targets of Fuzhengkangai

From: Investigate the mechanisms of Chinese medicine Fuzhengkangai towards EGFR mutation-positive lung adenocarcinomas by network pharmacology

Uniprot accession Gene names Protein name Log (Fold Change) Adjust P value
P07550 ADRB2 Beta-2 adrenergic receptor 1.02 1.63e-17
P10415 BCL2 Apoptosis regulator Bcl-2 1.20 1.49e-9
P38936 CDKN1A Cyclin-dependent kinase inhibitor 1 −1.01 4.79e-12
P28335 HTR2C 5-hydroxytryptamine receptor 2C 1.21 2.58e-16
Q12791 KCNMA1 Calcium-activated potassium channel subunit alpha-1 1.01 1.70e-8
P47712 PLA2G4A Cytosolic phospholipase A2 −1.33 3.70e-8
P17252 PRKCA Protein kinase C alpha type 1.06 3.69e-13
P61626 LYZ Lysozyme C 1.91 4.52e-17